2-in-1 adaptive design with dose optimization accounting for ranked dose response.

Area of Science:

• Clinical Trials Methodology
• Oncology Drug Development
• Biostatistics

Background:

• Adaptive clinical trial designs offer flexibility in oncology drug development.
• Seamless 2-in-1 designs aim to expedite the transition from early to late-stage trials.
• Current methods may not fully optimize for delayed treatment effects.

Purpose of the Study:

• To propose and evaluate a novel seamless 2-in-1 adaptive design for oncology clinical trials.
• To integrate Phase 2 dose-finding with Phase 3 confirmatory trials.
• To assess the statistical performance of the proposed design, considering dose rank and delayed treatment effects.

Main Methods:

• Development of a 2-in-1 adaptive design allowing Phase 2 expansion into Phase 3.
• Incorporation of selected dose rank into statistical testing procedures.
• Monte Carlo simulations to evaluate Type I error rate and statistical power.

Main Results:

• The proposed 2-in-1 adaptive design demonstrated favorable operating characteristics in simulations.
• The design is particularly advantageous when the treatment effect is delayed.
• Statistical validity (Type I error) and power were assessed under various scenarios.

Conclusions:

• The seamless 2-in-1 adaptive design offers an efficient pathway for oncology drug development.
• This innovative design is beneficial for drugs with delayed efficacy.
• The methodology accounts for dose selection and statistical rigor in adaptive trials.